Clovis Oncology Stock News

Investors piled into cancer stocks. Here's why.

Gainers Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) shares climbed 93.6% to $12.41 after the company announced a collaboration agreement with the University of Edinburgh to...

In a report released today, Kennen MacKay from RBC Capital maintained a Buy rating on Clovis Oncology (CLVS), with a price target of $17.00. The company's

In a report released today, Kennen MacKay from RBC Capital maintained a Buy rating on Clovis Oncology ( CLVS – Research Report ), with a price target of $17.00 . The company’s shares closed last M

Patrick Mahaffy has been the CEO of Clovis Oncology, Inc. (NASDAQ:CLVS) since 2009. This report will, first, examine...

Alliancebernstein L.P. trimmed its holdings in shares of Clovis Oncology (NASDAQ:CLVS) by 14.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The

One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze candidate. S3 Partners analyst Ihor Dusaniwsky...

Clovis (CLVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Clovis (CLVS) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Clovis Oncology (NASDAQ:CLVS) has entered into a private exchange agreement with a holder of its 2.50% Convertible Senior Notes due 2021.Pursuant to the agreement, the company will issue ~$36.05M 4.5

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Clovis Oncology (CLVS), with a price target of $27.00. The

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Clovis Oncology ( CLVS – Research Report ), with a price target of $27.00 . The company’s shares closed las

Clovis Oncology Inc: